UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 259

Sortiert nach

High Performance Computing: 9th Latin American Conference, CARLA 2022, Porto Alegre, Brazil, September 26-30, 2022, Revised Selected Papers

1st Edition 2022, 2022

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Volltextzugriff (PDF)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

JNCI : Journal of the National Cancer Institute, 2021-08, Vol.113 (8), p.1005-1016

2021

Volltextzugriff (PDF)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1349-1359

2021

Volltextzugriff (PDF)

Enhancing global access to cancer medicines

CA: a cancer journal for clinicians, 2020-03, Vol.70 (2), p.105-124

2020

Volltextzugriff (PDF)

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Volltextzugriff (PDF)

Optimal management of hormone receptor positive metastatic breast cancer in 2016

Therapeutic Advances in Medical Oncology, 2015-11, Vol.7 (6), p.304-320

2015

Volltextzugriff (PDF)

High Performance Computing: 10th Latin American Conference, CARLA 2023, Cartagena, Colombia, September 18-22, 2023, Revised Selected Papers

1, 2024

Volltextzugriff (PDF)

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Journal of clinical oncology, 2010-02, Vol.28 (6), p.1061-1068

2010

Volltextzugriff (PDF)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

NPJ breast cancer, 2021-01, Vol.7 (1), p.1-1, Article 1

2021

Volltextzugriff (PDF)

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2849-2853

2013

Volltextzugriff (PDF)

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3337-3344

2012

Volltextzugriff (PDF)

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

PloS one, 2018-08, Vol.13 (8), p.e0202865-e0202865

2018

Volltextzugriff (PDF)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC cancer, 2019-05, Vol.19 (1), p.517-517, Article 517

2019

Volltextzugriff (PDF)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

Therapeutic Advances in Medical Oncology, 2017-11, Vol.9 (11), p.693-709

2017

Volltextzugriff (PDF)

Boosting Advanced Computational Applications and Resources in Latin America through Collaboration and Sharing

Computing in science & engineering, 2018-05, Vol.20 (3), p.39-48

2018

Volltextzugriff (PDF)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Volltextzugriff (PDF)

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

NPJ breast cancer, 2021-09, Vol.7 (1), p.120-120, Article 120

2021

Volltextzugriff (PDF)

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil

JCO global oncology, 2021, Vol.7 (7), p.46-55

2021

Volltextzugriff (PDF)

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2018-11, Vol.379 (22), p.2108-2121

2018

Volltextzugriff (PDF)

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339

2020

Volltextzugriff (PDF)

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

NPJ breast cancer, 2022-09, Vol.8 (1), p.108-108, Article 108

2022

Volltextzugriff (PDF)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC cancer, 2019-06, Vol.19 (1), p.620-620, Article 620

2019

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)

JCO global oncology, 2021-12, Vol.7 (7), p.649-658

2021

Volltextzugriff (PDF)

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline

JCO global oncology, 2024-01, Vol.10 (10), p.e2300285-e2300285

2024

Volltextzugriff (PDF)

1 – 25 von 259

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(218)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(86)
Humans
(61)
Oncology
(51)
Female
(38)
Middle Aged
(33)
Adult
(28)
Male
(28)
Computer Science
(27)
Technology
(26)
Aged
(25)
Computer Science, Theory & Methods
(22)
Breast Cancer
(19)
Tumors
(19)
Biological And Medical Sciences
(16)
Aged, 80 And Over
(15)
Computer Science, Artificial Intelligence
(15)
Computer Science, Interdisciplinary Applications
(15)
Clinical Trials
(14)
Medical Sciences
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

High Performance Computing: 9th Latin American Conference, CARLA 2022, Porto Alegre, Brazil, September 26-30, 2022, Revised Selected Papers

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Enhancing global access to cancer medicines

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Optimal management of hormone receptor positive metastatic breast cancer in 2016

High Performance Computing: 10th Latin American Conference, CARLA 2023, Cartagena, Colombia, September 18-22, 2023, Revised Selected Papers

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

Boosting Advanced Computational Applications and Resources in Latin America through Collaboration and Sharing

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline

Aktive Filter

Suchergebnisse filtern